China is nearing the finish line in the coronavirus vaccines race with just “the last kilometer to go”, and its government is already negotiating with the WHO for potential global supplies.

Confidence in the vaccine has slipped in the US, regardless of political affiliation.

Touting its coronavirus vaccines as a "global public good", China is quietly preparing for the first general approvals and launches, possibly within weeks, developers say. But who will be first in line to receive them? And at what cost? Distribution and pricing are just some of the unanswered questions.

Clearance by UK regulator allows trial to restart, with pivotal US trial hoped to follow suit to keep AstraZeneca and Oxford's candidate on track for a potential late 2020 readout. Plus, new results with Sinovac's vaccine in the elderly and progress with antibodies.